Tumor infiltrating lymphocytes (TILs) as a predictive marker of pathological complete response (pCR) in a diverse patient population with early triple negative breast cancer (TNBC) treated with neoadjuvant real-world KEYNOTE-522 regimen

Breast Cancer Research and Treatment · Published 2026-06-01 · DOI 10.1007/s10549-026-08002-7

Free full text

Authors (9)

Riya Albert, Joshua Thomas, Navid Sadeghi, Sangeetha M. Reddy, Glenda Delgado Ramos, Heather McArthur, Samira Syed, Deborah Farr, Nisha Unni

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Albert, R., Thomas, J., Sadeghi, N., et al. (2026). Tumor infiltrating lymphocytes (TILs) as a predictive marker of pathological complete response (pCR) in a diverse patient population with early triple negative breast cancer (TNBC) treated with neoadjuvant real-world KEYNOTE-522 regimen. Breast Cancer Research and Treatment. https://doi.org/10.1007/s10549-026-08002-7

Related articles

• Methodological considerations on the predictive value of tumor-infiltrating lymphocytes for pathological complete response in early triple-negative breast cancer · Breast Cancer Research and Treatment · 2026 · Cites or is cited by this article · Same journal
• Retrospective study on regional nodal irradiation after omission of axillary lymph node dissection in sentinel lymph node-positive breast cancer: a propensity score matching analysis · Breast Cancer Research and Treatment · 2026 · Same journal
• Factors influencing discussion duration in breast cancer multidisciplinary team meetings: insights for streamlining care · Breast Cancer Research and Treatment · 2026 · Same journal
• Antacid co-treatment and pregnane X receptor genetic polymorphisms are survival determinants in patients treated with palbociclib · Breast Cancer Research and Treatment · 2026 · Same journal
• Curative-intent stereotactic ablative body radiation, surgery, and systemic therapy in non-osseous oligometastatic breast cancer · Breast Cancer Research and Treatment · 2026 · Same journal
• Early first-line systemic anticancer therapeutic attrition after metastatic recurrence in triple-negative breast cancer following neoadjuvant chemo-immunotherapy: a multicenter real-world study · Breast Cancer Research and Treatment · 2026 · Same journal
• Abemaciclib rechallenge after progression on abemaciclib plus endocrine therapy in patients with hormone receptor-positive HER2-negative metastatic breast cancer: results from the phase II again study (WJOG14220B) · Breast Cancer Research and Treatment · 2026 · Same journal
• Age-stratified difference in patient-reported health-related quality of life following breast cancer surgery · Breast Cancer Research and Treatment · 2026 · Same journal
• Rediscovering the Ciucci pathway: in-vivo evidence of a palmar lymphatic channel · Breast Cancer Research and Treatment · 2026 · Same journal
• Clinical implications of discordance in HER2 reassessment from HercepTest to 4B5 in metastatic breast cancer · Breast Cancer Research and Treatment · 2026 · Same journal